Key Developments: Catalyst Pharmaceutical Partners Inc (CPRX.O)
14 Mar 2014
Latest Key Developments (Source: Significant Developments)
Catalyst Pharmaceutical Partners Inc announced the pricing of an underwritten offering of 6,000,000 units, with each unit consisting of one share of its common stock and a warrant to purchase up to one share of its common stock, at a public offering price of $0.80 per unit. Catalyst expects to receive net proceeds of approximately $4.0 million (not including any cash proceeds from a future exercise of the warrants), after deducting the underwriting discount and estimated offering expenses. The warrants will have a five year term and an exercise price equal to $1.04 per share. The offering is expected to close on May 30, 2012. Cowen and Company, LLC is acting as sole book-running manager for the offering. ROTH Capital Partners is serving as a co-manager. The proceeds of this offering will be used to fund the activities necessary to support the submission of an NDA for CPP-109 for FDA approval and to begin to prepare for the commercial launch of CPP-109, assuming that the data from the ongoing Phase II(b) trial are compelling and the FDA accepts an NDA submitted by Catalyst for CPP-109 based on the data from the Phase II(b) trial; to manufacture sufficient CPP-115 for use in one or more future safety and/or proof-of-concept studies of CPP-115; and for general corporate purposes. Full Article
Catalyst Pharmaceutical Partners, Inc. Reports Positive Results From Phase I(a) Clinical Study Of CPP-115
Catalyst Pharmaceutical Partners, Inc. announced positive results from a Phase I(a) study to evaluate the safety, tolerability and pharmacokinetic (PK) profile of CPP-115, a small molecule drug candidate for the potential treatment of epilepsy (initially infantile spasms), cocaine addiction and other select CNS indications. The study results demonstrated that CPP-115 was well tolerated at all six doses administered. The key findings are No serious or severe adverse events. No cardiovascular or respiratory events. Rapidly absorbed (time to peak blood concentration about 30 minutes). Elimination half-life of four-six hours. Cmax increases in a dose proportional manner over the range of doses studied, 5-500 mg; whereas there is a greater than proportional increase in AUCs in the dose range. Top dose studied of 500 mg is greater than 10 times the predicted effective doses from animal models of 15-30 mg/day. Full Article
Jan 8 - Catalyst Pharmaceutical Partners Inc said a study showed its experimental drug to treat a rare autoimmune disorder did not have an adverse effect on the heart rate of patients.